Intratumoural Injection of a Novel NanoZolid®-Docetaxel Depot Formulation in Patients With Advanced Solid Tumours

Summary

This is a multicentre, open-label, first in man, study of a novel NanoZolid®-docetaxel depot formulation (NZ-DTX Depot) given as an intra-tumoural injection in patients with advanced solid tumours. The study includes a dose escalation part and a dose expansion part.

Timeline

Start

2019-02-28

Primary completion

2021-10-07

Completion

2021-10-07

Outcome

Outcome not reported

Stopped (Business): “Strategic decision”

Drugs

Indications